Skip to main content
Clinical Trials/NCT05718336
NCT05718336
Completed
Not Applicable

Atrial Fibrillation Trial To Eliminate Risk-factors

National Taiwan University Hospital1 site in 1 country343 target enrollmentMay 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atrial Fibrillation
Sponsor
National Taiwan University Hospital
Enrollment
343
Locations
1
Primary Endpoint
AF burden
Status
Completed
Last Updated
3 months ago

Overview

Brief Summary

The goal of this prospective-enrolling cohort study is to test and observe the effect of an integrated multi-discipline care program in patients with atrial fibrillation. The main questions it aims to answer are:

  1. to understand the baseline characteristics and to explore the occult risk factors of the patients with AF;
  2. to monitor the treatment efficacy of the patients undergoing integrated care and potentially concur the clinical obstacles that prevent the best care for patients with AF.

Participants will be treated by an integrated multi-discipline team that led by an electro-physiologist.

Detailed Description

Atrial fibrillation (AF) is a heart condition that potentially leads to heart failure and ischemic stroke. The prevalence of AF is increasing due to aging population and improved treatment in other cardiovascular field. This study is to execute integrated multi-discipline care in a tertiary hospital, and to observe the effect and the obstacle that the program might ensue.

Registry
clinicaltrials.gov
Start Date
May 1, 2020
End Date
August 31, 2024
Last Updated
3 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • At least 18 years old, who have been diagnosed with atrial fibrillation by a cardiologist with an electrocardiogram

Exclusion Criteria

  • Unable to complete the initial assessment and cooperate with the tracker
  • Those who refuse to sign the subject's consent

Outcomes

Primary Outcomes

AF burden

Time Frame: 0~24 months

The duration in AF on 14-day ECG monitor (percent)

Secondary Outcomes

  • MACE, major adverse cardiovascular event(0~24 months)

Study Sites (1)

Loading locations...

Similar Trials